QPHI will work with Sidra Medicine to shape the summit’s scientific programme and strengthen discussions on translating genomic research into clinical applications and preventive healthcare.

QATAR – Sidra Medicine and the Qatar Precision Health Institute (QPHI) have renewed their collaboration for the Precision Medicine and the Future of Genomics (PMFG) Summit 2026, with QPHI serving as strategic partner and co-organizer for the second consecutive year.
The partnership brings together two Qatar Foundation entities with complementary expertise in genomics, precision medicine and translational research.
QPHI will work with Sidra Medicine to shape the summit’s scientific programme and strengthen discussions on translating genomic research into clinical applications and preventive healthcare.
Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine and Executive Chair of PMFG 2026, said the continued collaboration reflects a shared commitment to turning genomic discoveries into practical healthcare solutions.
He noted that QPHI’s expertise in population-scale research and multi-omics complements Sidra Medicine’s clinical and translational capabilities.
Their combined experience covers different stages of precision healthcare, from scientific discovery to personalised treatment and disease prevention.
Advancing precision health through national collaboration
QPHI is a national centre for precision health research and implementation under Qatar Foundation.
The institute uses genomics, multi-omics and population-level data to support translational research and the development of personalised healthcare approaches.
Dr. Emmanouil Dermitzakis, President of QPHI and Chair of the PMFG Summit 2026 Leadership Committee, said Qatar’s precision health programme builds on a coordinated national strategy led by QPHI, with Sidra Medicine serving as a key clinical partner.
He noted that the summit provides an opportunity to share Qatar’s progress and exchange knowledge with international researchers and healthcare professionals.
As genomic technologies and precision medicine evolve, collaboration across institutions and countries remains important for translating research into healthcare practice.
Dr. Ammira Akil, Principal Investigator and Director of the Metabolic and Mendelian Translational Program at Sidra Medicine and Managing Chair of PMFG Summit 2026, said the partnership would help build on previous editions and connect scientific research with clinical implementation.
She highlighted the importance of including perspectives from the Global South, noting that equitable precision medicine requires greater representation of diverse populations in genomic research.
QPHI’s capabilities in genomics, data science and precision health have helped shape this year’s scientific programme.
Summit to address genomics, AI and equitable healthcare
The 12th PMFG Summit will take place from 7 to 9 December 2026 at the Qatar National Convention Centre in Doha.
The event builds on Sidra Medicine’s work in precision medicine and genomics, which began with the first precision medicine symposium in the Middle East in 2014.
The 2026 programme will cover four main areas: patient advocacy and next-generation therapeutics; global reference genomes and genomic representation across the Global South; artificial intelligence-driven discovery and digital medicine regulation; and the large-scale implementation of genomic medicine through biobanks, national programmes and paediatric care.
The summit will bring together clinicians, researchers, geneticists, bioinformaticians, data scientists, patient advocates, regulators, public health officials, policymakers and biotechnology companies.
Discussions will examine how advances in genomics, artificial intelligence and precision medicine can move beyond research laboratories into routine clinical care and public health programmes.
The programme will also create opportunities for collaboration among research institutions, healthcare providers, technology developers, and industry partners, particularly in applying genomic data and digital technologies to personalised healthcare.
Be the first to leave a comment